Kura Oncology has announced a significant milestone in its collaboration with Kyowa Kirin. The company received a $30 million payment following the dosing of the first patient in the KOMET-017 Phase 3 clinical trials for ziftomenib, an investigational oral menin inhibitor.
Kura Oncology’s Achievement in AML Treatment
This milestone comes after the launch of the KOMET-017 trials on September 29, 2025. These trials are designed to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML), specifically focusing on those with NPM1 mutations or KMT2A rearrangements.
Details of the KOMET-017 Trials
The KOMET-017 program consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 trials. It aims to assess the efficacy of ziftomenib for patients who meet specific genetic criteria. Kura believes that it is the only program working on menin inhibition in such a comprehensive manner.
About Kura Oncology
Kura Oncology is dedicated to advancing precision medicine in cancer treatment. The company’s focus includes small molecule drug candidates targeting specific cancer signaling pathways, addressing both hematologic malignancies and solid tumors.
Future Prospects
While the current news is promising, Kura acknowledges the uncertainties inherent in clinical trials. The company emphasizes that while ziftomenib shows potential, factors such as safety, efficacy, and regulatory approval remain critical considerations.
- Milestone Payment: $30 million
- Trial Start Date: September 29, 2025
- Trial Name: KOMET-017
- Target Conditions: NPM1-m and KMT2A-r AML
With this promising development, Kura Oncology is at the forefront of therapeutic innovation in AML treatment, and the outcomes of the KOMET-017 trials will be closely monitored by stakeholders in the oncology community.
